Hepatitis B Postexposure Prophylaxis in Preterm and Low-Birth-Weight Infants
AJP RepDOI: 10.1055/s-0035-1547329 Objective Recommendations for immunoprophylaxis in low-birth-weight (LBW) infants born to hepatitis B surface antigen (HBsAg)-positive mothers vary. We successfully immunized an HBsAg-exposed infant (birth weight: 400 g) and performed a literature review on the outcome of postexposure immunoprophylaxis in HBsAg-exposed preterm and LBW infants. Methods By use of PubMed we identified articles relevant to the topic. Studies were included if the intended vaccine schedule was completed and follow-up data were reported. Results Antibody response was reported in 31 LBW infants (birth weight
CONCLUSIONS: These findings suggest that most persons who inject drugs in Wisconsin are susceptible to HAV infection and that most persons aged ≥35 who inject drugs are susceptible to HBV infection. In addition to routine vaccination of children, targeted hepatitis vaccination programs should focus on adults who inject drugs to help prevent future infections. PMID: 31539482 [PubMed - as supplied by publisher]
Conclusion: Several health maintenance aspects are inadequately addressed by GIs and PCPs, in part because of conflicting perceptions of responsibility. Clear guidelines and better GI/PCP communication are required to ensure effective health maintenance for patients with IBD. PMID: 31528131 [PubMed]
Publication date: October 2019Source: American Journal of Preventive Medicine, Volume 57, Issue 4Author(s): Natalia V. Oster, Emily C. Williams, Joseph M. Unger, Polly A. Newcomb, Elizabeth N. Jacobson, M. Patricia deHart, Janet A. Englund, Annika M. HofstetterIntroductionCurrent U.S. recommendations state that newborns weighing ≥2,000 grams should receive a birth dose of hepatitis B vaccine, yet approximately one quarter do not receive this first dose as scheduled. The relationship between timely receipt of the first hepatitis B vaccine and other early childhood vaccines remains unclear.MethodsWashington State newborns...
This article was corrected online.
This JAMA Insights Clinical Update reviews updates in 2019 to the Advisory Committee on Immunization Practices (ACIP) adult immunization schedule, including recommendations for the Shingrix vaccine for prevention of zoster and of the Heplisav-B vaccine for prevention of hepatitis B virus infection.
THE GORDON WILSON LECTURE: THE HEPATITIS C VIRUS: FROM HIPPOCRATES TO CURE. Trans Am Clin Climatol Assoc. 2019;130:104-118 Authors: Alter HJ Abstract The modern age of viral hepatitis began in the early 1960s with the serendipitous discovery of the Australia antigen, a protein that was later shown to represent the envelope of the hepatitis B virus leading to its designation as the hepatitis B surface antigen. This was the first marker for any hepatitis virus and became not only a diagnostic assay, but also a mandatory blood donor screening test and the basis for the first generation hepatitis B vaccine...
From the Karolinska Institute in Stockholm, Vincent speaks with Niklas Björkström, Ali Mirazimi, and Matti Sällberg about their work on the impact of chronic hepatitis C virus infection on NK cells, Crimean-Congo hemorrhagic fever virus vaccines, and immunotherapy to block entry of hepatitis B and D viruses. Click arrow to play Download TWiV 565 (52 MB .mp3, […]
From the Karolinska Institute in Stockholm, Vincent speaks with Niklas Björkström, Ali Mirazimi, and Matti Sällberg about their work on the impact of chronic hepatitis C virus infection on NK cells, Crimean-Congo hemorrhagic fever virus vaccines, and immunotherapy to block entry of hepatitis B and D viruses. Hosts: Vincent Racaniello Guests: Niklas Björkström, Ali Mirazimi, and Matti Sällberg Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Karolinska Huddinge CCHV experimental vaccines (J Virol) Incre...
Conclusions: In HIV-1–infected subjects with AHB, the persistence of HBsAg seemed to occur frequently. Factors associated with a lower CBI risk were detectable HIV load and the use of dually acting antiretroviral treatment during AHB.